Search
Displaying 401–410 of 1063 results
-
Foundation Fighting Blindness Announces Leadership Changes
Foundation NewsJason Menzo named chief executive officer • Russell Kelley, PhD, MBA, appointed managing director of the RD Fund • Ben Yerxa, PhD, to lead Opus Genetics, the first RD Fund- and Foundation-backed spin-off company.
-
Research News
The newly approved drug reduces the pathologic hunger associated with BBS
-
Biologist and Father Dedicated to Daughter’s Cure
Beacon StoriesAfter Allison’s diagnosis with Usher syndrome type 3, her dad, Jeff Libby, wanted to do everything he could to find her a cure. As a biologist, Jeff started searching for organizations researching blinding diseases like Allison’s, and he found the Foundation Fighting Blindness.
-
In the Press
Funds to support advancement of two clinical trials through proof of concept: NPI-001 for retinitis pigmentosa in Usher syndrome and NPI-002 to slow cataract progression.
-
Over Thirty Presentations Highlighted during the 2022 Retinal Cell & Gene Therapy Innovation Summit
Research NewsIn its seventh year, the Retinal Cell & Gene Therapy Innovation Summit featured 34 presentations from industry experts from around the world.
-
Passionate Professional Outreach Volunteer Helping Newly Diagnosed
Beacon StoriesJim has always been avid about giving back to others, even after he was diagnosed with retinitis pigmentosa. And in the last few years, he’s begun working with the Foundation to help eye care professionals in the Cincinnati and Northern Kentucky area provide vital resources for their patients with retinal diseases.
-
Luxa Doses First Participant in Clinical Trial of RPE Stem Cells for Dry AMD Patients
Research NewsThe company’s RPESC-RPE cell product is composed of progenitor-stage RPE cells grown from human eyes donated to eye banks.
-
Beacon Stories
Mark Erelli has been a professional musician for the past twenty-three years. He’s always used songwriting to express himself. Since being diagnosed with retinitis pigmentosa, he’s needed music more than ever.
-
ProQR’s Sepofarsen Improves Vision Significantly for Girl with LCA10
Research NewsHowever, the Phase 2/3 Illuminate trial for sepofarsen didn’t meet its endpoints at 12 months
-
AGTC’s XLRP Gene Therapy Performs Well in Extension of Phase 2 Clinical Trial
Research NewsThe three-month results support the planned launch of the company’s Phase 2/3 Vista trial
